All 2026 dates on sale. Register before December 31!
January 2026 brought several key developments in aesthetic medicine. These changes reflect an ongoing evolution in patient care.
The neurotoxin market is segmenting by duration. This offers new options for patient-specific treatment plans. Clinical evidence also continues to emerge for regenerative approaches. This is especially true for patients with rapid volume loss.
Finally, aesthetic devices are securing expanded FDA clearances. This positions them for medical and rehabilitative use. These developments give practitioners new tools and evidence-based protocols to address diverse patient needs.
In this update, you’ll learn about:
Most physicians achieve competency in basic neurotoxins in 3-6 months, after treating 50+ patients. For more information on training, visit the IAPAM Botox Training Comparison Page.
The neurotoxin market is segmenting. This allows providers to match products to patient lifestyle, goals, and maintenance preferences. January 2026 brought two key developments at opposite ends of the duration spectrum.
Galderma announced the FDA accepted its Biologics License Application for RelabotulinumtoxinA (Relfydess). Key features include:
According to AbbVie’s announcement at IMCAS 2026, Allergan Aesthetics presented data for TrenibotulinumtoxinE. Its key features are:
Duration: 2-3 weeks. • Classification: A new category of ultra-short-acting neurotoxins (serotype E). • Use Case: Ideal for event-based treatments or for patients hesitant about longer-acting options.
According to Modern Aesthetics, the industry is moving toward biostimulation. Collagen-stimulating agents like PLLA and hyperdilute CaHA are used as scaffolds. They promote the deposition of proteoglycans, elastin, and collagen.
A study in Plastic and Aesthetic Nursing evaluated an exosome-containing skin booster with microneedling. Key findings include:
According to Fitt Insider’s analysis, GLP-1 medications are driving major growth:
Traditional HA fillers often underperform in GLP-1 patients. Biostimulatory approaches (CaHA, PLLA) address the underlying issue by promoting collagen production. For more on GLP-1 integration, see IAPAM’s January 2026 GLP-1 Practice Update.
The FDA approved oral Wegovy in late December 2025. Reuters reported 18,410 prescriptions in the first week. This will likely accelerate demand for post-weight-loss aesthetic treatments.
A meta-analysis in the Journal of Cosmetic Dermatology provided Level 1 evidence for non-surgical neck rejuvenation. Key findings:
For training on this technique, see IAPAM’s Platysma Bands Treatment Training for Physicians.
The FDA approved RHA Dynamic Volume for cheek augmentation. Key benefits:
According to The Aesthetic Guide, Morpheus8 secured the first FDA clearance for soft tissue contraction in fractional RF microneedling. This expands its use beyond purely aesthetic applications.
BTL’s Emsculpt Neo secured FDA clearance for stimulating neuromuscular tissue for rehabilitative purposes. This expands its market to post-surgery, rehabilitation, and athletes.
January 2026 expanded the clinical toolkit for aesthetic providers. The segmentation of neurotoxins, new data on regenerative approaches, and expanded device clearances provide more options to address diverse patient needs. Providers who integrate these advances can enhance their clinical offerings.
To stay at the forefront of this evolving field, consider becoming a Certified Aesthetic Provider™ (CAP). The IAPAM offers comprehensive, CME-accredited training in all aspects of aesthetic medicine, from injectables to regenerative therapies. Enroll in the CAP program today and demonstrate your commitment to the highest standards of care.
With new neurotoxin options, regenerative treatments, and device clearances entering the market, many providers are evaluating which services to add to their practice. The developments covered in this January 2026 update represent varying levels of capital investment and revenue potential.
Understanding the financial investment and return potential for each treatment category helps you make informed decisions about service expansion. Below is a breakdown of startup costs, per-treatment revenue, and break-even patient volumes across the treatment categories discussed in this update.
1. How do I decide which neurotoxin duration is right for my patient?
Base the selection on patient lifestyle and goals. Long-acting options suit busy patients. Short-acting options are ideal for events or first-timers.
2. What’s the difference between regenerative medicine and traditional fillers?
Traditional fillers replace volume. Regenerative approaches stimulate the body’s own collagen production.
3. How should I approach GLP-1 patients differently?
Prioritize biostimulatory approaches that promote collagen production. Intervene early during active weight loss for better outcomes.
4. Can I bill insurance for aesthetic devices with medical clearances?
Potentially, yes. It depends on your region, insurance contracts, and proper documentation of medical necessity.
5. Is neck treatment with neurotoxins safe and effective?
A: Yes. A recent meta-analysis demonstrated that it is safe and effective, with high patient satisfaction.
Earn your certification and designation as trusted Certified Aesthetic Provider™ (CAP) and show your patients your commitment to the highest standards in training and care.
From Botox® and fillers to PRP, PDO threads, chemical peels and more, this is your one stop shop for CME-accredited training from an internationally-recognized association with 20 years of aesthetic medicine excellence.
References
Contains: Emerging trends, expert discussions, recommendations, technique comparisons… and more!